Thyroid Nodules and Cancers in Children

----

An Overview in the Care of Children with Prader Willi Syndrome

Monday, November 2, 2020

VIRTUAL EXHIBIT HALL

  • Facebook
  • Twitter
  • Instagram
  • LinkedIn
8d24929b0ebd57e691ea9db331e1c1fa-youtube
8d24929b0ebd57e691ea9db331e1c1fa-youtube

Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases through the innovation, development and commercialization of life-changing therapies. Alexion is the global leader in complement inhibition and has developed and commercializes the first and only approved complement inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG).

For more information about Alexion, visit alexion.com.

At Endo International, our generics and specialty branded products play an important role in helping millions of patients lead healthier lives.

 

Through our operating companies, we are dedicated to delivering quality medicines to patients in need through excellence in development, manufacturing and commercialization.

For more information about Endo, visit endo.com.

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience, and Rare Diseases. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US).

 

The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products.

 

Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. 

For more information about Pfizer, please visit:

pfizer. com

Human Growth
Foundation

Headquarters:

997 Glen Cove Ave, Suite 5

Glen Head, New York 11545 USA

Email: hgf1@hgfound.org

Telephone: 1-800-451-6434

Fax Number: 1-516-671-4055

Human Growth Foundation (HGF)

is a  501(c)(3) non-profit organization.

 

Federal Tax Identification# 16-0913012  

Get HGF Updates

© 2020 by Human Growth Foundation. Created by D. Plump Consulting